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background: One injection of corifollitropin alfa replaces the ﬁrst seven daily FSH injections in controlled ovarian stimulation (COS)
cycles. Repeated treatment with therapeutic proteins may cause immune responses or hypersensitivity reactions. We assessed the immu-
nogenicity and safety of corifollitropin alfa treatment in up to three COS cycles.
methods: In this multicentre, phase III uncontrolled trial, patients (.60 kg) started treatment with one injection of 150 mg corifollitropin alfa
on cycle Day 2 or 3 of menses and 0.25 mg ganielix on stimulation Day 5 or 6. Primary outcome measures were antibody formation against
corifollitropin alfa (using highly sensitive radioimmunoprecipitation assay), hypersensitivity reactions, local tolerance and adverse events (AEs).
results: First, second and third COS cycles were started by 682, 375 and 198 patients, respectively. No clinically relevant immunogeni-
city or drug-related hypersensitivity was observed. For 192 patients undergoing their third cycle a post-treatment blood sample was negative
in the anti-corifollitropin antibody assay, resulting in an upper limit of the one-sided 95% conﬁdence interval (CI) of 1.5%. Most frequent AEs
were procedural pain (17.7%, 95% CI: 14.9–20.8%), headache (9.1%, 95% CI: 7.0–11.5%) and pelvic pain (7.6%, 95% CI: 5.7–9.9%).
Cumulative ongoing pregnancy rate after three cycles, including frozen-thawed embryo transfer cycles and spontaneous pregnancies, was
61% (95% CI: 56–65%) after censoring for patients who discontinued.
conclusions: Treatment with corifollitropin alfa can safely and effectively initiate and sustain ovarian stimulation during the ﬁrst 7 days
of COS in normal responder patients undergoing up to three treatment cycles, without concerns of immunogenicity.
The trial was registered under ClinicalTrials.gov identiﬁer NCT00696878.
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Introduction
Corifollitropin alfa is a recombinant fusion protein consisting of the
a-subunit of human FSH and a hybrid b-subunit composed of the
sequence of the b-subunit of human FSH and the carboxy-terminal
peptide of the b-subunit of hCG. Compared with recombinant (r) FSH,
corifollitropin alfa has a prolonged half-life and slower absorption to
peak serum levels (Fares et al., 1992; LaPolt et al., 1992; Duijkers et al.,
2002; Fauser et al., 2009). It has been demonstrated that corifollitropin
alfa can initiate and sustain follicular growth for 1 week (Duijkers et al.,
2002), so that a single injection can replace the ﬁrst seven daily injections
of gonadotrophin in each ovarian stimulation treatment cycle prior to
assisted reproduction. In view of the inverse relationship between
exposure and body weight, based on the results of the phase II dose-
ﬁnding study in combination with modelling and simulation, 100 and
150 mg corifollitropin alfa and a 60 kg body weight cut-off were selected
toresultinsimilarexposureand thereforesimilarovarianresponseforall
body weight groups (De Greef et al., 2010).
†The list of Trust investigators available in Appendix.
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may raise concerns of inducing an immune response or hypersensitiv-
ity reaction (Schellekens, 2002). To monitor the potential immuno-
genicity of corifollitropin alfa, a testing strategy was designed in line
with Mire-Sluis et al. (2004) to evaluate all patients exposed to corifol-
litropin alfa in up to three treatment cycles. The theoretical probability
of corifollitropin alfa being immunogenic (Schellekens, 2002)i n
humans is estimated to be low based on the molecular structure,
purity and formulation (Fauser et al., 2009). Also, it is injected only
once per treatment cycle with the majority of patients requiring no
more than three to four treatment cycles. To date, up to four injec-
tions of 15 mg corifollitropin alfa in hypogonadotrophic, hypogonadal
men (Bouloux et al., 2001) or a single injection of 100 or 150 mg cor-
ifollitropin alfa in more than 1000 patients has not induced any hyper-
sensitivity reaction or an immune response (Devroey et al., 2009; The
corifollitropin alfa Ensure study group, 2010).
The primary objective of the Trust trial was to assess the immuno-
genicity of repeated exposure to 150 mg corifollitropin alfa in a stan-
dard GnRH antagonist protocol in normal responder patients
weighing .60 kg with a normal BMI (18–29 kg/m
2) and a regular
menstrual cycle undergoing up to three cycles of controlled ovarian
stimulation (COS) with corifollitropin alfa for IVF and/or ICSI. In
addition, the overall safety and efﬁcacy of the new corifollitropin alfa
regimen used during sequential cycles was evaluated.
Materials and Methods
The Trust trial was a multicentre, open-label, uncontrolled clinical trial
carried out in 30 centres in Australia, Europe (Denmark, France,
Germany, Hungary, Italy, The Netherlands, Norway and Sweden) and
South America (Argentina, Brazil and Chile) between September 2006
and May 2009.
The study was conducted in accordance with principles of good clinical
practice and was approved by the appropriate institutional review boards
and regulatory agencies. Written informed consent was provided by all
subjects.
Study population
Patients aged 18–39 years with a body weight of .60 kg, a BMI of 18–
29 kg/m
2, menstrual cycle length within 24–35 days range, access to ejac-
ulatory sperm and an indication for COS for infertility using IVF or ICSI
were eligible to enrol in the study.
Patients were excluded from the study if one or more of the following
conditions were present: a history of, or any current (treated), endocrine
abnormality; clinically relevant abnormal laboratory values or chronic
disease; or relevant ovarian or tubal pathology that could interfere with
ovarian stimulation. Patients were also excluded if they had a prior
history of ovarian hyper-response or ovarian hyperstimulation syndrome
(OHSS) (.30 follicles ≥11 mm), polycystic ovary syndrome or .20
basal antral follicles on ultrasound (,11 mm, both ovaries combined).
Other exclusion criteria included a previously low ovarian response to
FSH or hMG treatment (i.e. cycle cancelled due to inadequate
ovarian response or three or less oocytes obtained), FSH or LH levels
.12 IU/L in the early follicular phase, more than three unsuccessful IVF
cycles since the last ongoing pregnancy or abnormal karyotype in the
subject or her partner.
Study design
The trial was designed to assess the safety, including the local and general
tolerance, of corifollitropin alfa in healthy female partners of infertile
couples undergoing COS for IVF or ICSI. For each subject, the trial
period covered one to three stimulated treatment cycles and no more
than six frozen-thawed embryo transfer (FTET) cycles from the ﬁrst two
treatment cycles. The study design per cycle is summarized in Fig. 1.
All subjects started their COS cycle on menstrual cycle Day 2 or 3
(stimulation Day 1). Subjects started stimulation with a single s.c. injection
of 150 mg (0.5 ml) corifollitropin alfa (Elonva
w, N.V. Organon, The Neth-
erlands). Injections were carried out by the patient herself (44.6%) or by a
medically qualiﬁed person (55.4%). From stimulation Day 8 onwards,
treatment was continued with a daily s.c. dose of FSH (follitropin alfa, folli-
tropin beta or menotropins) until the day of hCG administration (FSH
administration on the day of hCG administration was optional). The
maximum FSH dose for continuing treatment was 225 IU but this dose
could be reduced as appropriate. For normal responders, the rec-
ommended daily dose of FSH was 150 IU. The investigator was allowed
Figure 1 Treatment scheme during the ﬁrst stimulation cycle. In case patients did not become pregnant, the same treatment was applied in the
second and third stimulation cycle. Between two treatment cycles patients could have replacement of cryopreserved oocytes or embryos obtained
in a previous treatment cycle. ET, embryo transfer; rFSH, recombinant FSH.
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and including the day of hCG administration. If the ovarian response was
too high in the opinion of the investigator, the investigator was allowed to
cancel the cycle at any time. However, if there was a risk of OHSS, deﬁned
as .30 follicles ≥11 mm on transvaginal ultrasound, hCG was withheld
and the treatment cycle was cancelled per protocol. The maximum total
duration of stimulation was 19 days.
To prevent premature LH surges, a GnRH antagonist (0.25 mg; ganirelix
or cetrorelix acetate) was administered once daily starting on stimulation
Day 5 or 6 up to and including the day of hCG. Either urinary hCG
(10 000 IU or 5000 IU in case of a high ovarian response) or rhCG
(250 mg) was administered to induce ﬁnal oocyte maturation as soon as
three follicles ≥17 mm were observed by ultrasound. Investigators were
allowed to delay hCG administration for 1 day when preferred for practical
reasons.
Approximately 34–36 h after hCG administration, oocytes were
retrieved and standard IVF or ICSI was performed. At embryo transfer,
3 or 5 days after oocyte retrieval, a maximum of three embryos were
transferred. To support implantation and early pregnancy, progesterone
(≥600 mg/day vaginally) was started on the day of oocyte retrieval and
continued for 5–6 weeks or up to menses or a negative pregnancy test
performed at least 14 days after embryo transfer. Cryopreservation of
human embryos was, as per local embryo protection law, not allowed
in Chile, Germany and Italy: in these countries super numerous two
pronuclei oocytes instead of embryos were frozen.
Assessments
Before the start of COS, subjects underwent an hCG test to exclude preg-
nancy, a clinical examination and ultrasound scan to assess the number of
antral follicles, and each subject gave a blood sample for laboratory assess-
ments. On stimulation Day 1, 30 min after injection of corifollitropin alfa,
subjects underwent a clinical examination during which medical staff
assessed injection-site pain, itching, swelling and redness.
Subjects returned to the clinic on stimulation Day 5 or 6 (before the ﬁrst
administration of the GnRH antagonist) and Day 8 for assessment of the
size and number of follicles and hormone concentrations, and then at
least every other day up to and including the day of rhCG administration
for assessment of the size and number of follicles.
Immunogenicity
Immunogenicitywasdeterminedbymonitoringthedevelopmentofpotential
anti-corifollitropin alfa antibodies. A pretreatment and post-treatment
sample was obtained from each subject after each treatment cycle, 2
weeks after embryo transfer or 2–3 weeks after cycle discontinuation. To
monitorthepotentialimmunogenicityofcorifollitropinalfa,atestingstrategy
was designed to monitor all patients after each exposure to the drug up to
threetreatmentcycles.Forthatpurpose,ahighlysensitiveanti-corifollitropin
alfaantibodyassaywasdesignedandvalidatedaccordingtothewhitepaperof
Mire-Sluis et al. (2004). The screening assay was a validated, sensitive radio-
immunoprecipitation assay able to detect any immune response, regardless
of titre, afﬁnity or class of immunoglobulins (sensitivity 1.37 ng antibody/ml
serum). A patient-population-speciﬁc ﬂoating cut-off point was established
in serum samples from over 300 IVF patients collected at various time
points of the menstrual cycle. If a post-treatment samplewas above the pre-
deﬁned cut-off point, pretreatment and post-treatment samples were com-
pared to determine whether the response could be drug induced. Post-
treatment samples, which had a statistically higher assay response than pre-
treatmentsamplesasdeterminedbyapairedt-testandinwhichbindingafﬁn-
ity was depletable with corifollitropin alfa, were reported and further
evaluated to assess the titre and isotypes, speciﬁcity (cross-reactivity with
rFSH, rLH or hCG) and their neutralizing potential in an in vitro bioassay.
Adverse events
Adverse events (AEs) and serious AEs (SAEs) were assessed whenever
they occurred. AEs were deﬁned as any unfavourable sign, symptom or
disease that occurred during the study period. Moderate or severe local
tolerance reactions up to 24 h after any injection of corifollitropin alfa,
OHSS, ectopic pregnancy and miscarriage were always considered at
least an AE. OHSS was graded as mild, moderate or severe, according
to the OHSS guidelines (WHO Scientiﬁc Group, 1973). If the same
patient was reported with more than one grade of OHSS, only the
highest severity of OHSS was included.
SAEs were deﬁned as AEs that were life-threatening, required (pro-
longed) hospitalization or resulted in persistent or signiﬁcant disability or
incapacity.
End-points
The primary outcome measures were antibody formation against corifolli-
tropin alfa, hypersensitivity reactions, local tolerance and occurrence of
AEs or SAEs, including the incidence of OHSS.
The secondary outcome measures were efﬁcacy, determined for each
COS cycle, including the number of cumulus–oocyte complexes (COC)
retrieved, the number and quality of embryos obtained and transferred,
the ongoing pregnancy rates and the cumulative pregnancy rate.
Statistical analysis
A sample size of 600 subjects was planned, with the anticipation that 50%
of patients starting each cycle would start the subsequent cycle, thus giving
300 subjects starting Cycle 2 and 150 starting Cycle 3. If no immunogeni-
city to corifollitropin alfa was observed with 150 subjects undergoing three
treatment cycles, this allowed for an upper limit of the one-sided 95% con-
ﬁdence interval (CI) of 2%, the target set for this study.
The cumulative ongoing pregnancy ratewas calculated using the Kaplan–
Meierapproach(KaplanandMeier,1958)andincludedallongoingpregnan-
ciesfromthetreatmentregimen,includingfreshcycles,frozen-thawedcycles
and spontaneous pregnancies (Vail and Gardener, 2003). Patients who dis-
continuedtreatmentwithoutbecomingpregnantafterCycles1or2orafter
FTET cycles were censored assuming that patients who did not return for a
subsequent IVF cycle would have had the same chance of an ongoing preg-
nancy as patients who continued treatment.
Results
Patient characteristics and disposition
A total of 682 patients were included in the trial, 117 in Australia, 304
in Europe and 261 in South America. The mean (SD) age, body weight
and BMI were 32.9 (3.6) years, 67.0 (6.5) kg and 24.2 (2.4) kg/m
2,
respectively. The most frequently reported cause of infertility was
male factor (59.4%) followed by tubal factor (24.2%) and unexplained
infertility (19.2%). In total 392 subjects (57.5%) suffered from primary
infertility and 290 subjects (42.5%) presented with secondary infertil-
ity. The mean (SD) duration of infertility was 3.8 (3.0) years.
Of the 682 patients who started their ﬁrst COS treatment cycle
with corifollitropin alfa, 375 patients continued with a second cycle
and 198 patients started their third treatment cycle. Fig. 2 shows
the numbers of patients in each cycle continuing treatment at each
stage of the protocol.
The cancellation rate per cycle (i.e. patients who started treatment
but did not have embryo transfer in that cycle) was 9.7, 9.3 and 10.1%
for Cycles 1, 2 and 3, respectively. The overall reasons for cycle
2202 Norman et al.discontinuation are shown in Table I. Reasons for trial discontinuation
(not undergoing embryo transfer in Cycle 3) were AEs or SAEs (1.2%,
n ¼ 8, pregnancy (including spontaneous pregnancy) after treatment
Cycles 1 or 2 or after an FTET cycle (44.6%, n ¼ 304), withdrawal
of consent (12.8%, n ¼ 87), termination of the trial (4.7%, n ¼ 32),
non-SAE events in Cycle 3 (2.6%, n ¼ 18) and other reasons (8.1%,
n ¼ 55). Among the most frequent other reasons to discontinue
the trial were too high an ovarian response in the previous
treatment cycle(s) (2.9%, n ¼ 20) and too low an ovarian response
(1.2%, n ¼ 8).
Safety end-points
Immunogenicity
Post-treatment serum samples for assessment in the
anti-corifollitropin alfa antibody assay were available for 681 out of
682 (99.9%), 372 out of 375 (99.2%) and 192 out of 198 (97.0%)
patients who underwent one, two and three COS cycles, respectively.
All post-treatment samples were reported negative, with the
exception of one post-treatment sample taken after Cycle 2. This
sample appeared to have a statistically signiﬁcant increased binding
(P , 0.05) in the antibody assay that was depletable by corifollitropin
alfa and rFSH, but not by rLH or hCG. However, the binding of the
post-treatment sample was so low (titre 2) that isotyping was techni-
cally impossible. The post-treatment sample was without neutralizing
activity, thus it did not interfere with the bioactivity of corifollitropin
alfa or rFSH. For this subject no AEs were reported in either Cycle
1 or 2 and an additional blood sample taken 6 months after the pre-
vious sample tested negative. In view of the very low titre and the
absence of neutralizing activity, of moderate or severe local tolerance
reactions and of any AEs, the test result was judged as not clinically
relevant. The subject, who discontinued from the trial after Cycle 2,
became pregnant thereafter in a treatment cycle with daily FSH. The
upper limit of the one-sided 95% CI for the incidence of immunogeni-
city for subjects with three treatment cycles was 1.5%.
Hypersensitivity
No drug-related hypersensitivity reactions, including skin rash, urticaria,
hypotension, allergic asthma, chest tightness, bronchospasm, dyspnoea
and wheezing, were reported following injection of corifollitropin alfa.
Local tolerance at the injection site
Local tolerance reactions were mild, mainly redness and occurred in
2.5, 4.3 and 2.5% of patients in Cycles 1, 2, and 3, respectively.
There were no moderate or severe injection-site reactions (Table II).
........................................................
........................................................................................
Table I Patients discontinued from treatment cycles,
i.e. those who received corifollitropin alfa treatment
but did not undergo embryo transfer.
Treatment cycle
Cycle 1
(N 5 682)
Cycle 2
(N 5 375)
Cycle 3
(N 5 198)
Patients with cycle
discontinuation, n (%)
66 (9.7) 35 (9.3) 20 (10.1)
AE or SAE, n (%) 6 (0.9) 3 (0.8) 2 (1.0)
Insufﬁcient ovarian
response, n (%)
8 (1.2) 5 (1.3) 7 (3.5)
Risk of OHSS, n (%) 7 (1.0) 1 (0.3) 0 (0)
Too high ovarian
response
a, n (%)
9 (1.3) 6 (1.6) 1 (0.5)
Insufﬁcient number
and quality of oocytes
retrieved, n (%)
6 (0.9) 5 (1.3) 1 (0.5)
No or abnormal
fertilization, n (%)
18 (2.6) 9 (2.4) 3 (1.5)
Insufﬁcient number
and quality of embryos
for transfer, n (%)
6 (0.9) 3 (0.8) 5 (2.5)
Other reasons, n (%) 6 (0.9) 3 (0.8) 1 (0.5)
AE, adverse event; OHSS, ovarian hyperstimulation syndrome; SAE, serious adverse
event.
aIn the view of the investigator.
Figure 2 Flow of patients through the treatment cycles. FTET,
frozen-thawed embryo transfer.
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In Cycles 1, 2 and 3, 46.8, 35.2 and 31.3% of patients, respectively,
had at least one AE (Table II). Overall, including all treatment
cycles, the most common reported AEs were procedural pain
related to oocyte retrieval (17.7%, 95% CI: 14.9–20.8%), headache
(9.1%, 95% CI: 7.0–11.5%) and pelvic pain (7.6%, 95% CI: 5.7–
9.9%).The incidences of these AEs per treatment cycle are presented
in Table II. In Cycles 1, 2 and 3, 11.1, 3.7 and 2.0% of AEs were con-
sidered to be related to treatment.
AEs of severe intensity were uncommon, occurring in 2.5, 1.3 and
0.5% of patients in Cycles 1, 2 and 3, respectively. A total of 63 SAEs
were reported in 47 patients (6.9%) overall, and occurred in 3.4, 1.6
and 1.5% of patients, respectively according to COS treatment Cycles
1, 2 or 3. Among the reported SAEs were eight ectopic pregnancies,
two ruptured ectopic pregnancies, one heterotopic pregnancy, three
missed abortions, two spontaneous abortions and two imminent
abortions. In total, 15 SAEs were considered to be related to trial
medication, including all 10 occurrences of OHSS. In addition, one
subject in Cycle 1 with OHSS experienced a recoverable pulmonary
embolism.
Incidence of OHSS
OHSS was reported in 24 patients (3.5%) in their ﬁrst cycle of COS
and in seven patients (1.9%) in the second cycle and did not occur
during the third treatment cycle (Table II). One subject experienced
OHSS in Cycle 1 and Cycle 2. It should be noted that 25 subjects dis-
continued the trial after the ﬁrst (n ¼ 16) or after the second (n ¼ 9)
cycle because of too high an ovarian response or signs or symptoms of
OHSS. In total 15 cases of OHSS were considered mild, eight cases
were considered moderate and eight cases were reported as severe
OHSS. In the ﬁrst cycle, eight patients were hospitalized, one with
mild, one with moderate and six with severe OHSS. In the second
cycle, two patients with OHSS were hospitalized, one with mild and
one with severe OHSS. One subject who experienced severe OHSS
in the second cycle received ambulant treatment in the fertility clinic
and was not hospitalized.
.........................................................................................................
.............................................................................................................................................................................................
Table III Amount of recombinant FSH/hMG and hCG administered and numbers of cumulus–oocyte complexes
retrieved, embryos obtained and embryos transferred.
Treatment cycle
Cycle 1 (N 5 682) Cycle 2 (N 5 375) Cycle 3 (N 5 198)
Total dose of rFSH/hMG administered from Day 8 (IU)
a 400 (0, 2100) 450 (0, 1950) 450 (0, 2250)
Total duration of stimulation (days)
a 10 (7, 18) 10 (6, 19) 10 (7, 18)
Dose of hCG administered, n (%)
None 24 (3.5) 11 (2.9) 8 (4.0)
5000 IU (urinary) 60 (8.8) 25 (6.7) 10 (5.1)
10 000 IU (urinary) 439 (64.4) 245 (65.3) 132 (66.7)
250 mg (recombinant) 159 (23.3) 94 (25.1) 48 (24.2)
Number of cumulus–oocyte complexes per started cycle
b 11.9 (7.2) 11.5 (6.8) 11.3 (7.6)
Number of embryos obtained on Day 3
c 6.4 (4.5) 6.5 (4.4) 6.6 (4.8)
Number of good quality embryos obtained on Day 3
c 3.2 (3.1) 2.9 (2.8) 2.8 (2.7)
Number of embryos transferred
c 1.9 (0.7) 2.1 (0.7) 2.2 (0.7)
Number of good quality embryos transferred
d 1.4 (0.9) 1.5 (1.0) 1.6 (1.0)
aMedian (min, max) and restricted to patients with hCG injection.
bMean (SD); per started cycle.
cRestricted to subjects with IVF and/or ICSI.
dRestricted to subjects with embryo transfer.
........................................................................................
Table II Incidence of subjects with at least one
(serious) adverse event, with OHSS or with mild local
tolerance reaction.
Cycle 1
(N 5 682)
Cycle 2
(N 5 375)
Cycle 3
(N 5 198)
Subjects with
AEs, % (95% CI)
46.8 (43.0–
50.6)
35.2 (30.4–
40.3)
31.3 (24.9–
38.3)
Procedural pain 14.2 (11.7–
17.1)
11.2 (8.2–
14.8)
10.1 (6.3–
15.2)
Headache 5.6 (4.0–7.6) 5.3 (3.3–8.1) 5.6 (2.8–9.7)
Pelvic pain 4.8 (3.4–6.7) 3.7 (2.1–6.2) 2.5 (0.8–5.8)
Subjects with
SAEs,% (95% CI)
3.4 (2.1–5.0) 1.6 (0.6–3.4) 1.5 (0.3–4.4)
OHSS, any grade,
% (95% CI)
3.5 (2.3–5.2) 1.9 (0.8–3.8) 0
Mild 1.8 0.8
Moderate 0.9 0.5
Severe 0.9 0.5
Local tolerance
Mild,%
(95% CI)
2.5 (1.5–4.0) 4.3 (2.5–6.8) 2.5 (0.8–5.8)
CI, conﬁdence interval.
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In the ﬁrst, second and third treatment cycles, corifollitropin alfa was
self-administered by 39.9, 48.8 and 52.5% of the patients, respectively.
The hCG criteria were reached on stimulation Day 8 or before Day 8
for 122 subjects (17.9%) in Cycle 1, for 60 subjects (16.0%) in Cycle 2
and for 36 subjects (18.2%) in Cycle 3. The median dose of rFSH/hMG
was 150 IU per day in all three treatment cycles and the total median
dose was 400, 450 and 450 IU in Cycles 1, 2 and 3, respectively.
The majority of patients (.85%) ﬁnished their ﬁrst, second or third
cycle with rFSH and the minority (≤0.6%) used hMG. The duration
of stimulation (10 days) was consistent from Cycles 1 to 3 (Table III).
In total 50.6, 57.1 and 62.6% of patients in Cycles 1, 2 and 3,
respectively, started the GnRH antagonist on stimulation Day 5 and
47.4, 41.3 and 37.4% in Cycles 1, 2 and 3, respectively, started on
Day 6. The majority of patients received ganirelix (79.6, 82.7 and
96% in Cycles 1, 2 and 3, respectively) and a minority cetrorelix
(19.6, 15.5 and 3.5% in Cycles 1, 2 and 3, respectively). The
amount of urinary or rhCG administered in each cycle to trigger
ﬁnal oocyte maturation is given in Table III. The number of COCs
retrieved and embryos obtained and transferred were similar for the
three treatment cycles (Table III).
Pregnancy rates
Table IV shows the pregnancy rates for patients who started ovarian
stimulation with corifollitropin alfa, which was consistent over Cycles
1, 2 and 3. The ongoing pregnancy rate per started cycle was 22.7%
in the ﬁrst cycle, 20.5% in the second cycle and 20.7% in the third
cycle. However, the pregnancy rates varied widely among the 30 parti-
cipating sites: the 10th and 90th percentiles for the ongoing pregnancy
rate per site in Cycle 1 were 11.6 and 43.7%, respectively. Most ongoing
pregnancies were singletons (81.9–87.8% in each cycle). Of the 46 mul-
tiple pregnancies, 28 occurred in Cycle 1, 13 in Cycle 2 and 5 in Cycle
3. In Cycle 1 there were 26 twin and 2 triple pregnancies; in Cycle 2
there were 12 twin pregnancies and 1 triple pregnancy; and in Cycle
3 there were 5 twin pregnancies. The miscarriage rate per clinical preg-
nancy was 12.8, 12.5 and 14.6% for Cycles 1, 2 and 3, respectively.
In Cycle 1, coasting was applied in 15 patients with hCG injection
and 5 out of these 15 patients had an ongoing pregnancy (33.3%).
In Cycle 2, coasting was applied for 9 patients with hCG injection
and 1 patient became pregnant (11.1%). In Cycle 3, coasting was
applied for 1 patient who did not become pregnant.
The cumulative ongoing pregnancy rate after three COS cycles
including in-between FTET cycles and spontaneous pregnancies was
..............................................................
........................................................................................
Table IV For fresh cycles only: pregnancy rates per
started cycle and implantation rates per embryo
transfer.
Treatment cycle
Cycle 1
(N 5 682)
Cycle 2
(N 5 375)
Cycle 3
(N 5 198)
Biochemical
pregnancy (%)
a
31.4 28.5 27.8
Clinical
pregnancy (%)
b
26.2 23.5 24.2
Vital pregnancy
(%)
c
23.0 21.3 21.2
Ongoing
pregnancy (%)
d
22.7 20.5 20.7
Singletons 81.9 83.1 87.8
Twins 16.8 16.9 12.2
Triplets 1.3 1.3 0
Implantation
rate, % (n
e)
21.2 (n ¼ 616) 16.6 (n ¼ 340) 16.3 (n ¼ 178)
aBiochemical pregnancy: pregnancy proven by a biochemical pregnancy test or with
ultrasound showing at least one gestational sac.
bClinical pregnancy: presence of at least one gestational sac as assessed by
ultrasound.
cVital pregnancy: presence of at least one fetus with heart activity as assessed by
ultrasound.
dOngoing pregnancy: presence of at least one fetus with heart activity at least 10
weeks after embryo transfer or live birth.
ePatients with embryo transfer.
.............................................................................................................................................................................................
Table V Cumulative ongoing pregnancy rate: pregnancies after treatment, FTET cycles and spontaneous pregnancies.
Ongoing pregnancies Cumulative incidence 95% Conﬁdence interval
a
Cycle 1 155 0.23 0.20–0.26
Spontaneous pregnancies after cycle 1 11 0.25 0.22–0.28
FTET cycles between Cycle 1 and Cycle 2 37 0.31 0.27–0.35
Spontaneous pregnancies after the FTET cycles 4 0.32 0.28–0.35
Cycle 2 76
b 0.45 0.42–0.50
Spontaneous pregnancies after Cycle 2 8 0.47 0.43–0.52
FTET cycles between Cycle 2 and Cycle 3 11 0.50 0.46–0.54
Spontaneous pregnancies after the FTET cycles 3 0.51 0.47–0.55
Cycle 3 40
c 0.61 0.56–0.65
FTET, frozen-thawed embryo transfer.
aLimits of the 95% CI for the cumulative incidence rate.
bOne woman registered ongoing pregnancy twice, once in a FTET cycle between treatment Cycles 1 and 2 and once in Cycle 2; she was not counted as pregnant in Cycle 2 since per
protocol she discontinued the trial without being treated in another cycle.
cOne woman registered pregnancy in Cycles 2 and 3; she was only counted as pregnant in Cycle 2 since per protocol she discontinued the trial after her pregnancy in Cycle 2.
Safety of corifollitropin alfa in ovarian stimulation 220551%; after censoring for patients who discontinued treatment, the rate
was 61% (Table V).
Discussion
In the current trial, exposure to a single injection of corifollitropin alfa
in up to three repeated COS cycles using a standard GnRH antagonist
protocol in 682 patients weighing .60 kg with normal BMI and a
regular menstrual cycle was safe and well-tolerated without concerns
of immunogenicity. The antibody assay used was a highly sensitive
assay in which a relatively small difference between binding afﬁnity of
the pretreatment and post-treatment sample could lead to a statisti-
cally signiﬁcant increased binding to corifollitropin alfa. To assess
whether an elevated assay response was indicative of the presence
of corifollitropin alfa-speciﬁc antibodies or whether it concerned a
non-speciﬁc interaction, an immunodepletion assay was also per-
formed. The post-treatment sample of one patient in her second
treatment cycle was depletable with corifollitropin alfa and rFSH.
However, this sample was negative in the neutralizing activity assay,
and thus the antibodies did not interfere with the FSH bioactivity of
either gonadotrophin preparation.
There is in general limited information on immune responses to
therapeutic gonadotrophins in women undergoing treatment for infer-
tility. To date, two reviews have reported the absence of antibody
response to exogenous urinary or rFSH (Koren et al., 2002;
Wadhwa et al., 2003). The incidence of antibody formation against
hCG has been reported in hypogonadotrophic hypogonadal males
who received long-term treatment with urinary products resulting in
loss of efﬁcacy of the drug (reported incidence of antibody formation:
0–40%), but so far no antibodies have been reported in humans using
rhCG (Moudgal et al., 1997). The presence of circulating immunoglo-
bulins cross-reacting with endogenous FSH has been reported (Meyer
et al., 1990; Gobert et al., 2001; Haller et al., 2005; Haller et al., 2007);
however it is not stated whether these antibodies lowered the
endogenous FSH levels by neutralization. Anti-FSH antibodies may
be naturally occurring antibodies associated with peripheral FSH con-
centrations and produced in higher levels in infertile women (Haller
et al., 2007). Case reports have also been published on the presence
of (transient) anti-hCG antibodies in infertile women with recurrent
pregnancy loss (Pala et al., 1988; Amato et al., 2002).
In addition to the lack of antibody immune responses against cori-
follitropin alfa in this trial, there were also no treatment-related hyper-
sensitivity reactions; injection-site reactions were only mild in nature.
Lack of immunogenicity with repeated (n ¼ 3) cycles of corifollitropin
alfa treatment is consistent with the previous study of Bouloux et al.
(2001). This is also consistent with the ﬁndings of the Engage trial,
in which there were no drug-related immune responses to corifollitro-
pin alfa and no moderate or severe reactions at the injection site
(Devroey et al., 2009). In the current study, mild local tolerance reac-
tions were observed in fewer than 5% of subjects in each cycle. This is
similar to the reported 30 min local tolerance reactions in the Engage
trial when reactions were also only mild, 6.1% in the corifollitropin alfa
arm and 6.1% in the rFSH arm (Devroey et al., 2009).
In the current trial, the overall incidence of OHSS in the ﬁrst cycle
was 3.5 versus 7.0% in the Engage trial (Devroey et al., 2009) and the
incidence of moderate or severe cases of OHSS was 1.8 versus 3.9%
in the Engage trial. The lower incidence of OHSS in the trial reported
here is likely to be related to the patient population included, who
were slightly older (32.9 years in the current study versus 31.5
years in Engage) and who had a lower basal antral follicle count
(10.9 in the current study and 12.3 in Engage) (Devroey et al.,
2009). In addition, the current trial was conducted more closely in
line with current medical practice; only 43.5% of the patients received
FSH/hMG on the day of hCG for triggering ﬁnal oocyte maturation
and 23.3% of patients received 250 mg rhCG ( 6500 IU) instead of
10 000 IU urinary hCG. Furthermore, in patients who required
additional FSH injections from Day 8 onwards, a lower dose than
200 IU was more frequently given to complete ovarian stimulation.
The nature and incidence of reported SAEs other than OHSS
(ectopic pregnancies, procedural pain, pelvic pain, pelvic discomfort
and headache) were similar to those reported in both the corifollitro-
pin alfa and rFSH arms of the Engage trial (Devroey et al., 2009).
Concerning efﬁcacy variables, the mean number of COCs retrieved
per attempt was similar (11.9–11.3) across the three treatment
cycles, and the mean number of embryos (6.4–6.6) and good-quality
embryos (3.2–2.8) obtained was also consistent across the three
treatment cycles. The ongoing pregnancy rate per started cycle was
comparable between the three cycles which is in line with consistent
pregnancy rates across cycles in patients receiving their ﬁrst six cycles
of IVF treatment (Malizia et al., 2009). Since patients included were
not allowed more than three IVF cycles prior to the trial, none of
the patients had more than six treatment cycles.
Themean ongoingpregnancy rate in cycle1 was lower than hasbeen
reported previously for patients undergoing a similar COS treatment
regimen with corifollitropin alfa [22.7% in the current study compared
with 38.9% in the Engage trial (Devroey et al., 2009)]. However, there
was a considerable range of pregnancy rates among the different parti-
cipating sites with some sites providing high ongoing pregnancy rates
of over 40%. In contrast to the Engage trial, the current trial did not
include any IVF units within the USA, the latter often having higher
success rates than the rest of the world (Baker et al., 2010) but did
include IVF clinics in countries such as Italy, Germany and Chile with
restrictions in terms of embryo selection for transfer and cryopreserva-
tion of embryos/zygotes. This implied that in these clinics, maximally
three zygotes were kept in culture to develop into embryos and that
these embryos were transferred, regardless of their quality. In addition
to different IVF units contributing to the current trial outcome, the
patient population was slightly older than that in the Engage trial, with
a lower ovarian reserve, as mentioned before. Nevertheless, half of
the patients were pregnant after undergoing one, two or three treat-
ment cycles without any unexpected AEs, with very few cases of
OHSS and with an excellent local and general tolerance.
In conclusion, the results of this trial suggest that repeated treat-
ment cycles with a single injection of 150 mg corifollitropin alfa can
be safely and effectively applied in potential normal responder patients
undergoing COS prior to IVF or ICSI, without concerns for
immunogenicity.
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Appendix: Trust investigators
Argentina: Papier, CEGyR Buenos Aires; Vilela, IFER Buenos Aires; Bla-
quier, FERTILAB Riobamba, Buenos Aires; Ruhlmann, San Isidro
Safety of corifollitropin alfa in ovarian stimulation 2207Medicina, San Isidro; Botti, PROAR, Rosario; Pasqualini, Halitus,
Buenos Aires. Australia: Rombauts, Monash IVF, Clayton, Victoria;
Hale, Melbourne IVF, East Melbourne, Victoria; Watkins, Tasmania
IVF, Hobart; Norman, Repromed, Dulwich, SA and University of Ade-
laide; Illingworth, IVF Australia, Westmead, NSW. Brazil: Petracco,
Hospital de Sao Lucas, Porto Alegre-RS; Ferriani, Hospital das Clinicas
de Faculdade de Medicina de Ribeirao Preto, Ribeirao Preto. Chile:
Devoto, Instituto de Investigacion Materno Infantil (IDIMI), Santiago;
Zegers-Hochschild and Camus, Clinica las Condes, Santiago.
Germany: Schultze-Mosgau, Universita ¨tklinikum Lu ¨beck, Lu ¨beck; Diet-
erle, Kinderwunschcentrum Dortmund, Dortmund; Fiedler,
Kinderwunsch Centrum Mu ¨nchen, Mu ¨nchen. Denmark: Nyboe Ander-
sen, Rigshospitalet, København Ø. France: Salle, Groupement Hospita-
lier Est Hopital Femme Mere Infant PMA, Bron; Hazout, Clinique de la
Muette, Paris. Hungary: Konc, St Janos Hospital and Outpatient Insti-
tute, Budapest. Italy: La Sala, Arcispedale S. Maria Nuova, Reggio
Emilia; De Placido, Azienda Universitaria Policlinico Federico II,
Napoli. Netherlands: Laven, Erasmus Medisch Centrum, Rotterdam;
Lambalk, Academisch Ziekenhuis Vrije Universteit Amsterdam,
Amsterdam; Jansen, Reinier de Graaf Groep, Voorburg; Cohlen,
Isala Klinieken (locatie Sophia), Zwolle. Norway: Tanbo, Rikshospitalet
HF, Oslo. Sweden: Wramsby, IVF Kliniken St. Go ¨rans, Stockholm.
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